Author

A. Muik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 12 Organism:human· 10 Research Focus:drug response / drug discovery· 4 Assay:proteomics· 4 Organism:mouse· 2 Organism:non-human primate· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

U. Sahin· 9 shared H. Cai· 7 shared K. A. Swanson· 7 shared A.-K. Wallisch· 6 shared B. G. Lui· 6 shared D. Cooper· 5 shared J. Zou· 5 shared O. Tuereci· 5 shared

Activity by Year

2020-2023 · peak 8/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersImmunology

U. Sahin

Mutual co-authors in cluster

Author profile →

13 papers

Recent·Most cited

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine

K. Modjarrad, Y. Che, W. Chen, H. Wu, C. I. Cadima, A. Muik, M. S. Maddur, K. R. Tompkins, L. T. Martinez, H. Cai, M. Hong, S. Mensah, B. Cumbia, L. Falcao, J. S. Chang, , K. Swanson

The monovalent Omicron XBB.1.5-adapted BNT162b2 mRNA vaccine elicits stronger neutralizing antibody responses against XBB.1.5 and related sublineages than the bivalent Wild Type + Omicron BA.4/5 vaccine.

bioRxiv · Nov 17, 2023Immunology

Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T-cell recognition epitopes

A. Muik, B. G. Lui, H. Diao, Y. Fu, M. Bacher, A. Toker, J. Grosser, O. Ozhelvaci, K. Grikscheit, S. Hoehl, N. Kohmer, Y. Lustig, G. Regev-Yochay, S. Ciesek, K. Beguir, , U. Sahin

The paper examines how Omicron sublineages evade neutralizing antibodies but retain T-cell epitopes, suggesting T-cell immunity remains effective against these variants.

bioRxiv · Dec 15, 2022 · PreprintImmunology

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine

J. Zou, C. Kurhade, S. Patel, N. Kitchin, K. Tompkins, M. Cutler, D. Cooper, Q. Yang, H. Cai, A. Muik, Y. Zhang, D.-Y. Lee, U. Sahin, A. S. Anderson, W. C. Gruber, , P.-Y. Shi

This study compares the neutralizing antibody responses induced by monovalent and bivalent BA.4/5 vaccines against multiple Omicron sublineages in individuals over 55 years old, finding the bivalent vaccine elicits stronger neutralization.

bioRxiv · Nov 17, 2022 · PreprintMicrobiology

Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice

A. Muik, B. G. Lui, M. Bacher, A.-K. Wallisch, A. Toker, C. I. C. Couto, A. Gueler, V. Mampilli, G. J. Schmitt, J. Mottl, T. Ziegenhals, S. Fesser, J. Reinholz, F. Wernig, K.-G. Schraut, , U. Sahin

This study shows that exposure to BA.4/BA.5 spike glycoprotein enhances neutralizing antibody breadth against Omicron variants in vaccinated humans and mice.

bioRxiv · Sep 21, 2022 · PreprintImmunology

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5

A. Muik, B. G. Lui, M. Bacher, A.-K. Wallisch, A. Toker, A. Finlayson, K. Krueger, O. Ozhelvaci, K. Grikscheit, S. Hoehl, S. Ciesek, O. Tuereci, U. Sahin

The paper shows that BA.2 breakthrough infection in vaccinated individuals enhances neutralization of BA.2.12.1 and BA.4/BA.5 compared to BA.1 breakthrough infection.

bioRxiv · Aug 2, 2022Immunology

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection

C. Kurhade, j. Zou, H. Xia, M. Liu, Q. Yang, M. Cutler, D. Cooper, A. Muik, U. Sahin, K. U. Jansen, P. Ren, X. Xie, K. A. Swanson, P.-Y. Shi

This study evaluates the neutralization of Omicron sublineages and Deltacron by BNT162b2 vaccine or BA.1 infection, finding BA.4/5 shows highest evasion.

bioRxiv · Jun 5, 2022Microbiology

Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation

J. Quandt, A. Muik, N. Salisch, B. G. Lui, S. Lutz, K. Krueger, A.-K. Wallisch, P. Adams-Quack, M. Bacher, A. Finlayson, O. Ozhelvaci, I. Vogler, K. Grikscheit, S. Hoehl, U. Goetsch, , U. Sahin

bioRxiv · Apr 1, 2022 · PreprintImmunology

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

C. Kurhade, j. Zou, H. Xia, H. Cai, Q. Yang, M. W. Cutler, D. Cooper, A. Muik, K. Jansen, X. Xie, K. Swanson, P.-Y. Shi

This study assesses the neutralization of Omicron sublineages BA.1, BA.2, and BA.3 by BNT162b2 vaccine sera, finding reduced neutralization compared to the original SARS-CoV-2 strain.

bioRxiv · Mar 24, 2022Microbiology

Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine

H. Xia, J. Zou, C. Kurhade, H. Cai, Q. Yang, M. Cutler, D. Cooper, A. Muik, K. U. Jansen, X. Xie, K. A. Swanson, P.-Y. Shi

This study evaluates the neutralization of Omicron SARS-CoV-2 by two or three doses of the BNT162b2 vaccine, showing increased neutralization with three doses but reduced durability over time.

bioRxiv · Jan 21, 2022 · PreprintMicrobiology

BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants

J. Liu, Y. Liu, H. Xia, J. Zou, S. Weaver, K. A. Swanson, H. Cai, M. Cutler, D. Cooper, A. Muik, K. U. Jansen, U. Sahin, X. Xie, P. R. Dormitzer, P.-Y. Shi

The paper assesses the neutralization ability of BNT162b2-elicited sera against SARS-CoV-2 variants, finding that all sera neutralize variants to titers of ≥80, indicating vaccine effectiveness against emerging strains.

bioRxiv · Sep 13, 2021 · PreprintMicrobiology

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

A. Muik, A.-K. Wallisch, B. Saenger, K. A. Swanson, J. Muehl, W. Chen, H. Cai, R. Sarkar, O. Tuereci, P. R. Dormitzer, U. Sahin

The paper assesses the neutralizing activity of BNT162b2 vaccine-induced sera against SARS-CoV-2 B.1.1.7 pseudoviruses and finds equivalent neutralizing titers compared to the Wuhan strain.

bioRxiv · Jan 18, 2021Immunology

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

A. B. Vogel, I. Kanevsky, Y. Che, K. A. Swanson, A. Muik, M. Vormehr, L. M. Kranz, K. C. Walzer, S. Hein, A. Gueler, J. Loschko, M. S. Maddur, A. Ota-Setlik, K. Tompkins, J. Cole, , M. R Gutman

This paper evaluates two BNT162b vaccine candidates in non-human primates, showing they are immunogenic and protect against SARS-CoV-2 infection.

bioRxiv · Dec 11, 2020 · PreprintImmunology

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

A. Vogel, I. Kanevsky, Y. Che, K. Swanson, A. Muik, M. Vormehr, L. Kranz, K. Walzer, S. Hein, A. Gueler, J. Loschko, M. Maddur, K. Tompkins, J. Cole, B. G. Lui, , Ciolin

This paper reports on a prefusion SARS-CoV-2 spike RNA vaccine that induces strong immune responses and prevents lung infection in non-human primates.

bioRxiv · Sep 8, 2020 · PreprintImmunology